Met interacts with EGFR and Ron in canine osteosarcoma.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Veterinary and Comparative Oncology

• Publication date

  2013-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/j.1476-5829.2011.00309.xPMID 22235915PMCID PMC3969615
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Gefitinib

  2012cited by this paper
• HGF-independent Potentiation of EGFR Action by c-Met

  2011cited by this paper
• Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin

  2010cited by this paper
• Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency.

  2010cited by this paper
• EGFR/Met association regulates EGFR TKI resistance in breast cancer

  2010cited by this paper
• Synthetic lethality screens reveal RPS6 and MST1R as modifiers of insulin-like growth factor-1 receptor inhibitor activity in childhood sarcomas.

  2010cited by this paper
• The expression of epidermal growth factor receptor and its downstream signaling molecules in osteosarcoma.

  2009cited by this paper
• From concept to reality: the long road to c-Met and RON receptor tyrosine kinase inhibitors for the treatment of cancer.

  2009cited by this paper
• Expression of Hepatocyte Growth Factor and the Proto-oncogenic Receptor c-Met in Canine Osteosarcoma

  2009cited by this paper
• met oncogene activation qualifies spontaneous canine osteosarcoma as a suitable pre‐clinical model of human osteosarcoma

  2009cited by this paper
• Crosstalk in Met receptor oncogenesis.

  2009cited by this paper
• The Prognostic Significance of RON and MET Receptor Coexpression in Patients with Colorectal Cancer

  2008cited by this paper
• Signaling networks assembled by oncogenic EGFR and c-Met

  2008cited by this paper
• Dual MET–EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer

  2008cited by this paper
• Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors

  2008cited by this paper
• Transcription-Dependent Epidermal Growth Factor Receptor Activation by Hepatocyte Growth Factor

  2008cited by this paper
• Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells.

  2008cited by this paper
• Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer

  2008cited by this paper
• Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells.

  2008cited by this paper
• Met-related receptor tyrosine kinase Ron in tumor growth and metastasis.

  2008cited by this paper
• Cross talk between c-Met and epidermal growth factor receptor during retinal pigment epithelial wound healing.

  2007cited by this paper
• MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

  2007cited by this paper
• Epidermal growth factor receptor in osteosarcoma: expression and mutational analysis.

  2007cited by this paper
• Comparative biology of human and canine osteosarcoma.

  2007cited by this paper
• MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

  2007cited by this paper
• Epidermal Growth Factor Receptor Expression in High-Grade Osteosarcomas Is Associated with a Good Clinical Outcome

  2007cited by this paper
• Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells

  2007cited by this paper
• A novel small molecule Met inhibitor, PF2362376, exhibits biological activity against osteosarcoma.

  2007cited by this paper
• Evaluation of Gefitinib for Treatment of Refractory Solid Tumors and Central Nervous System Malignancies in Pediatric Patients

  2006cited by this paper
• Prognostic Significance of Co-expression of RON and MET Receptors in Node-Negative Breast Cancer Patients

  2005cited by this paper
• Small molecules with EGFR-TK inhibitor activity.

  2005cited by this paper
• Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder

  2005cited by this paper
• RON, a Tyrosine Kinase Receptor Involved in Tumor Progression and Metastasis

  2005cited by this paper
• Tyrosine kinases as targets for cancer therapy.

  2005cited by this paper
• Mitogen-activated protein kinases in apoptosis regulation

  2004cited by this paper
• The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness.

  2003cited by this paper
• Update on the biology and management of canine osteosarcoma.

  2003cited by this paper
• A randomized controlled trial of octreotide pamoate long-acting release and carboplatin versus carboplatin alone in dogs with naturally occurring osteosarcoma: evaluation of insulin-like growth factor suppression and chemotherapy.

  2002cited by this paper
• STEALTH liposome-encapsulated cisplatin (SPI-77) versus carboplatin as adjuvant therapy for spontaneously arising osteosarcoma (OSA) in the dog: a randomized multicenter clinical trial

  2002cited by this paper
• The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy.

  2001cited by this paper
• The role of ERK 1/2 and p38 MAP-kinase pathways in taxol-induced apoptosis in human ovarian carcinoma cells.

  2001cited by this paper
• A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.

  2001cited by this paper
• The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinoma

  2000cited by this paper
• Cross-talk between Epidermal Growth Factor Receptor and c-Met Signal Pathways in Transformed Cells*

  2000cited by this paper
• Cross-talk between the proto-oncogenes Met and Ron

  2000cited by this paper
• Epidermal growth factor receptor signaling activates met in human anaplastic thyroid carcinoma cells.

  2000cited by this paper
• The prognostic significance of amplification and overexpression of c‐met and c‐erb B‐2 in human gastric carcinomas

  2000cited by this paper
• The prognostic significance of amplification and overexpression of c‐met and c‐erb B‐2 in human gastric carcinomas

  1999cited by this paper
• Switching signals on or off by receptor dimerization.

  1998cited by this paper
• Co‐expression and regulation of Met and Ron proto‐oncogenes in human hepatocellular carcinoma tissues and cell lines

  1997cited by this paper
• The HGF receptor family: unconventional signal transducers for invasive cell growth

  1996cited by this paper
• Constitutive activation of the RON gene promotes invasive growth but not transformation

  1996cited by this paper
• A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family.

  1994cited by this paper
• Interaction between heterologous receptor tyrosine kinases

  1991cited by this paper
• Platelet-derived growth factor (PDGF) stimulates PDGF receptor subunit dimerization and intersubunit trans-phosphorylation.

  1991cited by this paper
• Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function

  1990cited by this paper
• Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function.

  1990cited by this paper
• Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

  1984cited by this paper

• Bispecific c-Met/PD-1 CAR-T Cells Have Enhanced Therapeutic Effects on Solid Tumor

  2025cites this paper
• Comparative aspects of targeted sentinel lymph node mapping in veterinary and human medicine: opportunities for future research

  2024cites this paper
• Protein tyrosine phosphatase non-receptor type 12 suppresses tumor progression in osteosarcoma cells.

  2022cites this paper
• Canine osteosarcoma in comparative oncology: Molecular mechanisms through to treatment discovery

  2022cites this paper
• Immunohistochemical expression of proliferation markers in canine osteosarcoma

  2022cites this paper
• Molecular targets for anticancer therapies in companion animals and humans: what can we learn from each other?

  2021cites this paper
• Molecular Characterisation of Canine Osteosarcoma in High Risk Breeds

  2020cites this paper
• AKT and JUN are differentially activated in mesenchymal stem cells after infection with human and canine oncolytic adenoviruses

  2020cites this paper
• Prognostic role of the recepteur d'origine nantais (RON) expression in primary high-grade osteosarcoma.

  2020cites this paper
• Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer

  2019cites this paper
• Ursolic acid suppresses the biological function of osteosarcoma cells.

  2019cites this paper
• Canine sarcomas as a surrogate for the human disease

  2018cites this paper
• miR-182 regulates trastuzumab resistance by targeting MET in breast cancer cells

  2018cites this paper
• The RTK Interactome: Overview and Perspective on RTK Heterointeractions.

  2018cites this paper
• Tumoren des Skeletts

  2017cites this paper
• Receptor tyrosine kinase expression and phosphorylation in canine nasal carcinoma.

  2017cites this paper
• Comparative review of human and canine osteosarcoma: morphology, epidemiology, prognosis, treatment and genetics

  2017cites this paper
• Effects of epidermal growth factor receptor kinase inhibition on radiation response in canine osteosarcoma cells

  2016cites this paper
• The Role of OFD1 in the Pathogenesis of Polycystic Kidney Disease

  2015cites this paper
• Dasatinib Modulates Invasive and Migratory Properties of Canine Osteosarcoma and has Therapeutic Potential in Affected Dogs

  2015cites this paper
• Epidermal growth factor signaling in transformed cells.

  2015cites this paper
• Comparative oncology: what dogs and other species can teach us about humans with cancer

  2015cites this paper
• Utilization of a canine cancer cell line (FACC) panel in comparative and translational studies of gene expression and drug sensitivity

  2015cites this paper
• Inhibitors of HGFA, Matriptase, and Hepsin Serine Proteases: A Nonkinase Strategy to Block Cell Signaling in Cancer.

  2014cites this paper
• Analysis of predisposition factors for limb amputation in dogs with survival analysis in those diagnosed with appendicular cancer

  2014cites this paper
• Hepatocyte growth factor-like protein is a positive regulator of early mammary gland ductal morphogenesis.

  2014cites this paper
• OFD1 and Flotillins Are Integral Components of a Ciliary Signaling Protein Complex Organized by Polycystins in Renal Epithelia and Odontoblasts

  2014cites this paper
• Canine osteosarcoma: a naturally occurring disease to inform pediatric oncology.

  2014cites this paper
• Comparative analysis of the surface exposed proteome of two canine osteosarcoma cell lines and normal canine osteoblasts

  2013cites this paper
• Tyrosine kinase inhibitor special issue.

  2012cites this paper
• Evaluation of Expression and Function of VEGFR 2 , PDGFRα , PDGFRβ , KIT

  2012influential citation
• Tumors of the Skeletal System

  2012cites this paper